Serum Homocysteine, Folate, and Vitamin B₁₂ Levels in Patients with Systemic Lupus Erythematosus: A Meta-Analysis and Meta-Regression

References

• Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcón GS, Winkelmayer WC, Costenbader KH. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with medicaid coverage, 2000–2004. Arthritis Rheum. 2013;65(3):753–63. doi:10.1002/art.37795.
   PubMedGoogle Scholar
• Nasonov E, Soloviev S, Davidson JE, Lila A, Ivanova R, Togizbayev G, Omarbekova Z, Shevchuk S, Iaremenko O, Gnylorybov A, et al. The prevalence and incidence of Systemic Lupus Erythematosus (SLE) in selected cities from three commonwealth of independent states countries (the Russian Federation, Ukraine and Kazakhstan). Lupus. 2014;23(2):213–9. doi:10.1177/0961203313512881.
   PubMed Web of Science ®Google Scholar
• Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. 1997;145(5):408–15. doi:10.1093/oxfordjournals.aje.a009122.
   PubMed Web of Science ®Google Scholar
• McMahon M, Hahn BH, Skaggs BJ. Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol. 2011;7(2):227–41. doi:10.1586/eci.10.98.
   PubMed Web of Science ®Google Scholar
• Steed MM, Tyagi SC. Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. Antioxid Redox Signal. 2011;15(7):1927–43. doi:10.1089/ars.2010.3721.
   PubMed Web of Science ®Google Scholar
• Debreceni B, Debreceni L. The role of homocysteine-lowering B-vitamins in the primary prevention of cardiovascular disease. Cardiovasc Ther. 2014;32(3):130–8. doi:10.1111/1755-5922.12064.
   PubMed Web of Science ®Google Scholar
• Antoniades C, Shirodaria C, Leeson P, Baarholm OA, Van-Assche T, Cunnington C, Pillai R, Ratnatunga C, Tousoulis D, Stefanadis C, et al. MTHFR 677 C > T Polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis. Circulation. 2009;119(18):2507–15. doi:10.1161/circulationaha.108.808675.
   PubMed Web of Science ®Google Scholar
• Kelemen LE, Anand SS, Hegele RA, Stampfer MJ, Rosner B, Willett WC, Montague PA, Lonn E, Vuksan V, Teo KK, et al. Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians. Atherosclerosis. 2004;176(2):361–70. doi:10.1016/j.atherosclerosis.2004.06.003.
   PubMed Web of Science ®Google Scholar
• Panayiotou A, Nicolaides A, Griffin M, Tyllis T, Georgiou N, Martin RM, Bond D, Tziakouri-Shiakalli C, Fessas C, Deltas C, et al. Serum total homocysteine, folate, 5,10-methylenetetrahydrofolate reductase (MTHFR) 677C->T genotype and subclinical atherosclerosis. Expert Opin Ther Targets. 2009;13(1):1–11. doi:10.1517/14728220802560281.
   PubMed Web of Science ®Google Scholar
• Thambyrajah J, Townend JN. Homocysteine and atherothrombosis-mechanisms for injury. Eur Heart J. 2000;21(12):967–74. doi:10.1053/euhj.1999.1914.
   PubMed Web of Science ®Google Scholar
• He Y, Li Y, Chen Y, Feng L, Nie Z. Homocysteine level and risk of different stroke types: a meta-analysis of prospective observational studies. Nutr Metab Cardiovasc Dis. 2014;24(11):1158–65. doi:10.1016/j.numecd.2014.05.011.
   PubMed Web of Science ®Google Scholar
• Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015;14:6. doi:10.1186/1475-2891-14-6.
   PubMed Web of Science ®Google Scholar
• Khandanpour N, Loke YK, Meyer FJ, Jennings B, Armon MP. Homocysteine and peripheral arterial disease: systematic review and meta-analysis. Eur J Vasc Endovasc Surg: Off J Eur Soc Vasc Surg. 2009;38(3):316–22. doi:10.1016/j.ejvs.2009.05.007.
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976;60(2):221–5. doi:10.1016/0002-9343(76)90431-9.
   PubMed Web of Science ®Google Scholar
• Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol. 2012;176(8):708–19. doi:10.1093/aje/kws130.
   PubMed Web of Science ®Google Scholar
• Thacker SG, Berthier CC, Mattinzoli D, Rastaldi MP, Kretzler M, Kaplan MJ. The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol. 2010;185(7):4457–69. doi:10.4049/jimmunol.1001782.
   PubMed Web of Science ®Google Scholar
• Stojan G, Petri M. Atherosclerosis in systemic lupus erythematosus. J Cardiovasc Pharmacol. 2013;62(3):255–62. doi:10.1097/FJC.0b013e31829dd857.
   PubMed Web of Science ®Google Scholar
• Weber C, Meiler S, Döring Y, Koch M, Drechsler M, Megens RTA, Rowinska Z, Bidzhekov K, Fecher C, Ribechini E, et al. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J Clin Invest. 2011;121(7):2898–910. doi:10.1172/jci44925.
   PubMed Web of Science ®Google Scholar
• Rho YH, Chung CP, Oeser A, Solus J, Raggi P, Gebretsadik T, Shintani A, Stein CM. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol. 2008;35(9):1789–94.
   PubMed Web of Science ®Google Scholar
• Asanuma Y, Chung CP, Oeser A, et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol. 2006;33:539–45.
   PubMed Web of Science ®Google Scholar
• Wong CK, Lit LCW, Tam LS, Li EKM, Wong PTY, Lam CWK. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol (Orlando, Fla). 2008;127(3):385–93. doi:10.1016/j.clim.2008.01.019.
   PubMed Web of Science ®Google Scholar
• Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S. Vascular stiffness in women with systemic lupus erythematosus. Hypertension. 2001;37(4):1075–82. doi:10.1161/01.hyp.37.4.1075.
   PubMed Web of Science ®Google Scholar
• van Guldener C, Robinson K. Homocysteine and renal disease. Semin Thromb Hemost. 2000;26(3):313–24. doi:10.1055/s-2000-8407.
   PubMed Web of Science ®Google Scholar
• do Prado R, D'Almeida VM, Guerra-Shinohara E, et al. Increased concentration of plasma homocysteine in children with systemic lupus erythematosus. Clin Exp Rheumatol. 2006;24:594–8.
   PubMed Web of Science ®Google Scholar
• Lloyd W, Schur PH. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore). 1981;60(3):208–17. doi:10.1097/00005792-198105000-00004.
   PubMed Web of Science ®Google Scholar
• Fijnheer R, Roest M, Haas FJ, et al. Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study. J Rheumatol. 1998;25:1737–42.
   PubMed Web of Science ®Google Scholar
• Giannelou M, Nezos A, Fragkioudaki S, Kasara D, Maselou K, Drakoulis N, Ioakeimidis D, Moutsopoulos HM, Mavragani CP. Contribution of MTHFR gene variants in lupus related subclinical atherosclerosis. Clin Immunol. 2018;193:110–7. doi:10.1016/j.clim.2018.02.014.
   PubMed Web of Science ®Google Scholar